India Pharma Outlook Team | Thursday, 02 July 2026
India may need to rethink its India drug rules before making changes that could impact the country's position as a global leader in affordable medicines.
Dr Reddy’s Chairman Satish Reddy has warned that India should not accept regulatory data protection terms just to attract foreign investment.
He said such a move could weaken the generic drug industry, which has helped India earn the title of the "pharmacy of the world" by supplying low-cost medicines to millions across the globe.
Speaking about the ongoing policy debate, Reddy said protecting innovation is important, but it should not come at the cost of India's strong generic medicines business. According to him, any changes to India drug rules must strike a balance between encouraging research and preserving the country's competitive edge in generics.
The debate centers around regulatory data protection (RDP), also known as data exclusivity. Under the current system, Indian generic drug makers can rely on existing clinical trial data once a drug patent expires. This allows them to introduce affordable versions of medicines without repeating expensive and time-consuming clinical trials.
If regulatory data protection is introduced, generic companies would be barred from using that clinical data for a fixed period even after patent expiry. Instead, they would have to generate fresh clinical data, delaying product launches and increasing development costs.
For companies like Dr Reddy’s, which have built their business on speed and scale in the generic drug industry, such a policy could:
Reddy cautioned that India should not adopt such rules simply to attract foreign investment if they end up weakening one of the country's biggest pharmaceutical strengths.
Also Read: The Strategic Role of Regional Corridors in Future-Ready MedTech
While defending the generic drug industry, Reddy also stressed that India must invest more in drug discovery and innovation.
He said India's innovation ecosystem remains fragmented, with research institutions, hospitals, government agencies, and pharmaceutical companies often working independently instead of together. According to him, the country needs a national mission that connects these stakeholders, similar to successful models followed by countries such as China and South Korea.
Reddy also highlighted the need for better funding across different stages of drug development. While early-stage research receives some support, companies often struggle to secure funding as projects move into costly clinical trials.
He added that government procurement could also encourage innovation by providing a stable market for newly developed medicines, giving companies more confidence to invest in long-term research.
Reddy believes AI in healthcare will play an important role in the future of the pharma industry, particularly by speeding up drug discovery, improving clinical trials, and making regulatory processes more efficient.
However, he made it clear that artificial intelligence is not a complete solution. Regulatory systems will also need to evolve to ensure proper human oversight, patient safety, and reliable clinical outcomes.
For investors, the discussion around India drug rules remains an important development to monitor. Any move toward regulatory data protection or data exclusivity could reshape competition for major generic drug makers, including Dr Reddy, Cipla, Sun Pharma, and other Indian pharmaceutical companies.
At the same time, the industry's long-term growth will depend on its ability to balance innovation with affordability. As India aims to build a stronger research ecosystem while maintaining its leadership in generic medicines, policy decisions taken today could shape the future of the country's pharmaceutical sector for years to come.
Dr Reddy's Laboratories is one of India's leading pharmaceutical companies, with a presence in generics, biosimilars, active pharmaceutical ingredients (APIs), and innovative medicines. The company operates in more than 60 countries and is known for developing affordable healthcare solutions while expanding its research and development capabilities.
.jpg)
